These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16037656)

  • 1. [Variability of efficacy measures in Alzheimer's disease].
    Musicco M; Pettenati C; Caltagirone C
    Ann Ist Super Sanita; 2005; 41(1):87-91. PubMed ID: 16037656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the therapeutic effects in individual patients with Alzheimer disease].
    Richard E; Lemstra AW; Walstra GJ; van Gool WA
    Ned Tijdschr Geneeskd; 2001 Feb; 145(8):340-5. PubMed ID: 11257811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations.
    Conway EL
    Clin Neuropharmacol; 1998; 21(1):8-17. PubMed ID: 9579280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galantamine for Alzheimer's disease and mild cognitive impairment.
    Cusi C; Cantisani TA; Celani MG; Incorvaia B; Righetti E; Candelise L;
    Neuroepidemiology; 2007; 28(2):116-7. PubMed ID: 17409773
    [No Abstract]   [Full Text] [Related]  

  • 6. Donepezil in the treatment of patients with Alzheimer's disease.
    Tsuno N
    Expert Rev Neurother; 2009 May; 9(5):591-8. PubMed ID: 19402770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
    Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
    Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
    J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical inquiries. Does treatment with donepezil improve memory for patients with mild cognitive impairment?
    Stiles MM; Martin S; Persons RK
    J Fam Pract; 2006 May; 55(5):435-6. PubMed ID: 16670040
    [No Abstract]   [Full Text] [Related]  

  • 10. Memantine (Ebixa) in clinical practice - results of an observational study.
    Calabrese P; Essner U; Forstl H
    Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A neuropsychological test battery for use in Alzheimer disease clinical trials.
    Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
    Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-Alzheimer drugs: ethical aspects of research and practice].
    Berghmans RL
    Tijdschr Gerontol Geriatr; 2000 Jun; 31(3):100-6. PubMed ID: 10900662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research design issues: antialuminum drug studies in Alzheimer's disease.
    Shore D; Wyatt RJ
    Clin Neuropharmacol; 1982 Dec; 5(4):337-43. PubMed ID: 7159877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
    Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.